Table 2.

Baseline statistics and longitudinal change for SF-36 measures.

	Baseline mean (SD)	Estimated change per year after initiation of ocrelizumab (estimate (95% CI); p-value)
Physical Functioning	38.4 (13.2); n = 101	0.6; 95% CI: −0.7, 1.8; p = 0.378
Role-Physical	37.3 (11.6); n = 100	2.5; 95% CI: 0.2, 4.7; p = 0.033
Bodily Pain	44.1 (11.6); n = 106	0.9; 95% CI: −0.8, 2.6; p = 0.292
General Health	38.7 (9.8); n = 104	1.7; 95% CI: 0.1, 3.2; p = 0.035
Vitality	39.3 (10.7); n = 105	2.1; 95% CI: 0.5, 3.7; p = 0.011
Social Functioning	44.2 (10.3); n = 104	0.5; 95% CI: −1.3, 2.3; p = 0.579
Role-Emotional	40.0 (11.7); n = 103	3.9; 95% CI: 1.6, 6.2; p = 0.001
Mental Health	46.8 (9.7); n = 105	1.5; 95% CI: −0.1, 3.1; p = 0.059
Physical Component Summary	37.7 (11.0); n = 89	1.0; 95% CI: −0.5, 2.5; p = 0.205
Mental Component Summary	45.1 (9.6); n = 89	2.4; 95% CI: 0.5, 4.3; p = 0.013

Bold values indicate statistically significant associations (p < 0.05).